Daewoong Pharmaceutical to launch the third clinical trial of Nabota in China
Daewoong Pharmaceutical to launch the third clinical trial of Nabota in China
  • Kim Min-jee
  • 승인 2020.01.02 02:12
  • 댓글 0
이 기사를 공유합니다

Source = Daewoong Pharmaceutical


“Nabota,” which is a botulinum toxin product developed by Daewoong Pharmaceutical, is going to start its third clinical trial in China.

Daewoong Pharmaceutical announced on Dec. 31 that it has started a three-phase clinical trial of Nabota in China and conducted a meeting of clinical researchers at the Fullman Skyway Hotel in Shanghai, China, on Dec. 28. It is planning to release its products in China in 2022.

About 60 people, including Lee Chung-bong, the Chinese clinical director and professor at the 9th Shanghai Transportation University Hospital, clinical researchers and hospital officials, attended the meeting. The three-phase progress plan was announced and a question-and-answer session was conducted.

Daewoong Pharmaceutical plans to enter the Chinese market as an indication of its adaptation to improve frown lines. It compares comparators and effects for about 500 people for 16 weeks to prove non-inferiority and safety. Clinical trials will be conducted at 12 institutions, including the 9th hospital of Shanghai Transportation University Hospital, which is famous for its plastic surgery in China.

“China has the largest number of patients in the world, while its market penetration rate is low at around 2 percent, and there are only two officially licensed drugs, making it the most anticipated market for future growth," said Park Sung-soo, head of the Nabota business division at Daewoong Pharmaceutical.

Nabota, meanwhile, won a sales permit from the U.S. Food and Drug Administration (FDA) in February.

삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • #1206, 36-4 Yeouido-dong, Yeongdeungpo-gu, Seoul, Korea(Postal Code 07331)
  • 서울특별시 영등포구 여의도동 36-4 (국제금융로8길 34) / 오륜빌딩 1206호
  • URL: www.koreaittimes.com / m.koreaittimes.com. Editorial Div. 02-578-0434 / 010-2442-9446. Email: info@koreaittimes.com.
  • Publisher: Monica Younsoo Chung. CEO: Lee Kap-soo. Editor: Jung Yeon-jin. Juvenile Protection Manager: Yeon Choul-woong.
  • IT Times Canada: Willow St. Vancouver BC, Canada / 070-7008-0005.
  • Copyright(C) Korea IT Times, Allrights reserved.